Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Survival Outcomes After Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Baseline Tumor Features

  • By

  • Mike Wenzel

  • Quynh Chi Le

  • Carolin Siech

  • Benedikt Hoeh

  • Konrad Klimek

  • Christian Happel

  • Fred Saad

  • Felix Preisser

  • Derya Tilki

  • Markus Graefen

  • Thomas Steuber

  • Tobias Maurer

  • Maximilian C. Kriegmair

  • Pierre I. Karakiewicz

  • Felix K. H. Chun

  • Daniel Groener

  • Philipp Mandel

  • October 20, 2026

Share

Clinical Report: Survival Outcomes After Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer by Baseline Tumor Features

Related Resources & Content

  1. ASCO Publications — Survival outcomes of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving lutetium-177-PSMA-617 (Lu) based on line of therapy.
  2. ASCO Publications — Treatment patterns and survival outcomes among lutetium 177–experienced patients with metastatic castration-resistant prostate cancer.
  3. ASCO Publications — Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.
  4. ASCO Publications — Overall survival after 177Lu-PSMA-617 molecular radiotherapy in patients with metastatic castrate-resistant prostate cancer: Post-hoc analysis of a prospective phase II trial.
  5. FDA expands Pluvicto’s metastatic castration-resistant prostate cancer indication | FDA
  6. Approval Label_215833s035lbl.pdf
  7. Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial - PMC

Original Source(s)

Survival outcomes with Lutetium-177-PSMA-617 in metastatic castration-resistant prostate cancer patient according to baseline tumor characteristics

  • by Mike Wenzel, Quynh Chi Le, Carolin Siech, Benedikt Hoeh, Konrad Klimek, Christian Happel, Fred Saad, Felix Preisser, Derya Tilki, Markus Graefen, Thomas Steuber, Tobias Maurer, Maximilian C. Kriegmair, Pierre I. Karakiewicz, Felix K. H. Chun, Daniel Groener, Philipp Mandel

  • October 20, 2026

Related Content

Impact of AI-Assisted Endoscopy on Secondary Review and Referral Decisions in Gastric Cancer Screening: A Multicenter Real-World Study

2026 ASCO Breast Cancer Highlights: SENOMAC

Harold Burstein, MD, PhD, and Laura S. Dominici, MD, FACS, discuss highlights from the SENOMAC trial which sheds light on whether some patients with early breast cancer and limited lymph node involvement can safely avoid additional axillary surgery.

  • October 15, 2026

  • 1 min
2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

  • October 15, 2026

  • 1 min